These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23798620)

  • 1. A novel method for the direct determination of heparin concentration during cardiopulmonary bypass surgery.
    Haselbach S; Maurer J; Vogel V; Harder S; Weber CF; Baykut D; Meininger D; Keller H; Moritz A; Mäntele W
    Clin Chem Lab Med; 2013 Oct; 51(10):2037-43. PubMed ID: 23798620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
    Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test.
    Wallock M; Jeske WP; Bakhos M; Walenga JM
    Perfusion; 2001 Mar; 16(2):147-53. PubMed ID: 11334198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of ACT as measured with three commercially available devices with circulating heparin level during cardiac surgery.
    Niles SD; Sutton RG; Ploessl J; Pennell B
    J Extra Corpor Technol; 1995 Dec; 27(4):197-200. PubMed ID: 10172651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
    Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged Activated Clotting Time after Protamine Administration Does Not Indicate Residual Heparinization after Cardiopulmonary Bypass in Pediatric Open Heart Surgery.
    Yamamoto T; Wolf HG; Sinzobahamvya N; Asfour B; Hraska V; Schindler E
    Thorac Cardiovasc Surg; 2015 Aug; 63(5):397-403. PubMed ID: 26121380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation.
    Koster A; Despotis G; Gruendel M; Fischer T; Praus M; Kuppe H; Levy JH
    Anesth Analg; 2002 Jul; 95(1):26-30, table of contents. PubMed ID: 12088937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automated protamine dose assay in heparin reversal management after cardiopulmonary by pass.
    Guarracino F; De Cosmo D; Penzo D; Tedesco M; Bossi A; Zussa C; Polesel E; De Stefani R
    Minerva Anestesiol; 2001 Apr; 67(4):165-9. PubMed ID: 11376504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Point-of-care measurement of activated clotting time for cardiac surgery as measured by the Hemochron signature elite and the Abbott i-STAT: agreement, concordance, and clinical reliability.
    Dirkmann D; Nagy E; Britten MW; Peters J
    BMC Anesthesiol; 2019 Sep; 19(1):174. PubMed ID: 31492108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring incomplete heparin reversal and heparin rebound after cardiac surgery.
    Galeone A; Rotunno C; Guida P; Bisceglie A; Rubino G; Schinosa Lde L; Paparella D
    J Cardiothorac Vasc Anesth; 2013 Oct; 27(5):853-8. PubMed ID: 23627997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance of blood heparin concentration rather than activated clotting time better preserves the coagulation system in hypothermic cardiopulmonary bypass.
    Shirota K; Watanabe T; Takagi Y; Ohara Y; Usui A; Yasuura K
    Artif Organs; 2000 Jan; 24(1):49-56. PubMed ID: 10677157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi.
    Hellstern P; Bach J; Simon M; Saggau W
    J Extra Corpor Technol; 2007 Jun; 39(2):81-6. PubMed ID: 17672188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
    Despotis GJ; Joist JH
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole blood heparin concentrations do not correlate with plasma antifactor Xa heparin concentrations in pediatric patients undergoing cardiopulmonary bypass.
    Gruenwald C; de Souza V; Chan AK; Andrew M
    Perfusion; 2000 Jun; 15(3):203-9. PubMed ID: 10866421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real time measurement of heparin concentration during cardiopulmonary bypass.
    Hashimoto K; Sasaki T; Hachiya T; Takakura H; Onoguchi K; Nagahori R; Takeuchi S
    J Cardiovasc Surg (Torino); 1999 Oct; 40(5):645-51. PubMed ID: 10596996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The activated coagulation time: suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery.
    Martindale SJ; Shayevitz JR; D'Errico C
    J Cardiothorac Vasc Anesth; 1996 Jun; 10(4):458-63. PubMed ID: 8776637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Feb; 85(2):174-85. PubMed ID: 6823136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjusted calculation model of heparin management during cardiopulmonary bypass in obese patients: A randomised controlled trial.
    Vienne M; Haas E; Wipf T; Grunebaum L; Levy F; Sattler L; Hoang Minh T; Severac F; Tacquard C; Collange O; Mertes PM; Steib A
    Eur J Anaesthesiol; 2018 Aug; 35(8):613-620. PubMed ID: 29521662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery.
    Vonk AB; Veerhoek D; van den Brom CE; van Barneveld LJ; Boer C
    J Cardiothorac Vasc Anesth; 2014 Apr; 28(2):235-41. PubMed ID: 24342152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.